Author: Carvacho, Ingrid; Piesche, Matthias
Title: RGDâ€binding integrins and TGFâ€Î² in SARSâ€CoVâ€2 infections – novel targets to treat COVIDâ€19 patients? Cord-id: lk8m50w7 Document date: 2021_3_18
ID: lk8m50w7
Snippet: The new coronavirus SARSâ€CoVâ€2 is a global pandemic and a severe public health crisis. SARSâ€CoVâ€2 is highly contagious and shows high mortality rates, especially in elderly and patients with preâ€existing medical conditions. At the current stage, no effective drugs are available to treat these patients. In this review, we analyse the rationale of targeting RGDâ€binding integrins to potentially inhibit viral cell infection and to block TGFâ€Î² activation, which is involved in the sever
Document: The new coronavirus SARSâ€CoVâ€2 is a global pandemic and a severe public health crisis. SARSâ€CoVâ€2 is highly contagious and shows high mortality rates, especially in elderly and patients with preâ€existing medical conditions. At the current stage, no effective drugs are available to treat these patients. In this review, we analyse the rationale of targeting RGDâ€binding integrins to potentially inhibit viral cell infection and to block TGFâ€Î² activation, which is involved in the severity of several human pathologies, including the complications of severe COVIDâ€19 cases. Furthermore, we demonstrate the correlation between ACE2 and TGFâ€Î² expression and the possible consequences for severe COVIDâ€19 infections. Finally, we list approved drugs or drugs in clinical trials for other diseases that also target the RGDâ€binding integrins or TGFâ€Î². These drugs have already shown a good safety profile and, therefore, can be faster brought into a trial to treat COVIDâ€19 patients.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and local delivery: 1
- acute ards respiratory distress syndrome and local vascular inflammation: 1
- acute ards respiratory distress syndrome and low efficacy: 1, 2
- acute ards respiratory distress syndrome and low expression: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and lung brain: 1, 2, 3, 4, 5, 6, 7, 8
- acute ards respiratory distress syndrome and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lung disease case: 1
- acute ards respiratory distress syndrome and lung epithelium: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute ards respiratory distress syndrome and lung examination: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- acute ards respiratory distress syndrome and lung parenchyma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- acute ards respiratory distress syndrome and lung repair: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute ards respiratory distress syndrome and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- additional study and low expression: 1
- additional study and lung cancer: 1, 2
- additional study and lung disease: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date